Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC - Targeted Oncology
A 57-year-old woman with cirrhosis, Crohn disease, and chronic hepatitis B presented with abdominal pain and fatigue. Diagnosed with stage IV hepatocellular carcinoma (HCC), she was treated with lenvatinib due to her autoimmune disease. Lenvatinib was supported by the REFLECT trial, showing noninferior overall survival and superior progression-free survival compared to sorafenib. The patient had a partial response initially but discontinued treatment due to disease progression. Observational data suggest lenvatinib may be favorable for Child-Pugh B patients.
Related Clinical Trials
Highlighted Terms
Related News
A 57-year-old woman with cirrhosis, Crohn disease, and chronic hepatitis B presented with abdominal pain and fatigue. Diagnosed with stage IV hepatocellular carcinoma (HCC), she was treated with lenvatinib due to her autoimmune disease. Lenvatinib was supported by the REFLECT trial, showing noninferior overall survival and superior progression-free survival compared to sorafenib. The patient had a partial response initially but discontinued treatment due to disease progression. Observational data suggest lenvatinib may be favorable for Child-Pugh B patients.